Podcasts about target discovery institute

Sir Peter Ratcliffe, Director of Clinical Research at the Francis Crick Institute, as well as Director of Oxford University's Target Discovery Institute – has dedicated his life to understanding the body's molecular-level response to low oxygen levels, or ‘hypoxia'. He received the 2019 Nobel prize for Physiology or Medicine, along with two Americans, William Kaelin of Harvard and Gregg Semenza of Johns Hopkins, for successfully tackling one of physiology's greatest puzzles - how our bodies sense and adapt so quickly to a lack of oxygen, at high altitude for example, or during sudden exercise. He talks to Jim about how his early medical career led him into a deeply unfashionable area of medicine that would solve how and why our bodies are so clever at being able to fine tune themselves to keep functioning under a range of conditions. His early ground breaking discoveries may have been initially turned down by a major scientific journal, but he would go on to pave the way for promising new strategies to fight anaemia and many other challenging diseases, most notably cancer. Producer Adrian Washbourne

Housed within the Target Discovery Institute, the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. The burden caused by Alzheimer's disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.

Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Professor Jens Rittscher has a joint appointment between the Ludwig Institute for Cancer Research, the Target Discovery Institute and the Department of Engineering Science. His research aims to enhance our understanding of complex biological processes through the analysis of image data acquired at the microscopic scale.

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Professor Jens Rittscher has a joint appointment between the Ludwig Institute for Cancer Research, the Target Discovery Institute and the Department of Engineering Science. His research aims to enhance our understanding of complex biological processes through the analysis of image data acquired at the microscopic scale.

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Professor Jens Rittscher has a joint appointment between the Ludwig Institute for Cancer Research, the Target Discovery Institute and the Department of Engineering Science. His research aims to enhance our understanding of complex biological processes through the analysis of image data acquired at the microscopic scale.

Kip Harry, Conference Director at Cambridge Healthtech Institute discusses Ubiquitin Proteasome System drug discovery with Dr. Benedikt Kessler, Ph.D., University Research Lecturer, Ubiquitin Proteolysis Group, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford Discussion Questions Include: • What are the most present opportunities in this space? (Another way to ask that): What are some of the most promising UPS targets currently being investigated, and within which indications? • What challenges have slowed the progress of generating lead molecules targeting various components of the UPS? • Why are Deubiquitinases (DUBs) emerging as viable therapeutic targets? • Are there drug discovery challenges specific to targeting DUB enzymes vs. ligases? If so, what are they? • What are some novel tools and technologies being developed/implemented to overcome some of these challenges? • What do you hope to convey to attendees during your lecture this fall at the Ubiquitin Proteasome System meeting? • What is on the horizon for research in this space? (Another way to ask that): What are future goals that need to be accomplished to push these novel medicines further into the clinic?

Meet our Target Discovery Institute. The Target Discovery Institute (TDI) is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.